| abstract |
The present invention relates to a compound of formula (I), wherein R1 and R2 are each independently H, C1-C6 alkyl, -CH2CH (OH) CH2NH2, among others; R3 and R5 are H or - (C1-C6) alkyl; R4 is H, - (C1-C6) alkyl, - (C1-C6) alkyl-OH, among others; or R3 and R4 combine to form a heterocycloalkyl ring; or R4 and R5 and the carbon atom to which they are attached form a cyclopropyl ring; R6, R7 and R8 are each independently H, fluoro, among others; R9 and R10 are H, - (C1-C6) alkyl, among others; R11 and R12 are each independently H, -NH2, among others; R11 and R18 combine to form an optionally substituted heterocycloalkyl ring and R12 is H; R15, R16, R17 and R18 are each independently H, - (C1-C6) alkyl, among others; X is optionally substituted - (C1-C6) alkyl-, among others; Y is a link, -O-, -S-, among others; Z is H, halogen, -NH2, among others; R27 and R28 are independently halogen, nitro, hydroxyl, among others; p and q are 0 to 2; or a pharmaceutically acceptable salt thereof. . These compounds are inhibitors of bacterial signal peptidase type 1 (SpsB), an essential protein in bacteria; being useful to treat bacterial infections whose pathogens are resistant to multiple drugs. It also refers to compositions that contain them. |